JP2021522172A - 軟骨ホーミングペプチドの複合体 - Google Patents

軟骨ホーミングペプチドの複合体 Download PDF

Info

Publication number
JP2021522172A
JP2021522172A JP2020557208A JP2020557208A JP2021522172A JP 2021522172 A JP2021522172 A JP 2021522172A JP 2020557208 A JP2020557208 A JP 2020557208A JP 2020557208 A JP2020557208 A JP 2020557208A JP 2021522172 A JP2021522172 A JP 2021522172A
Authority
JP
Japan
Prior art keywords
peptide
complex
seq
complex according
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020557208A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019209662A5 (https=
JP2021522172A5 (https=
Inventor
ジーン グレゴリー ホッピング，
ジーン グレゴリー ホッピング，
ジュリアン エー． サイモン，
ジュリアン エー． サイモン，
チュンフェン イン，
チュンフェン イン，
クリストファー メーリン，
クリストファー メーリン，
サンガー， ミシェル エル． クック
サンガー， ミシェル エル． クック
アンドリュー ジェイムズ マイア，
アンドリュー ジェイムズ マイア，
ジョゼフ マイケル ビーティー，
ジョゼフ マイケル ビーティー，
ジェイムズ オルソン，
ジェイムズ オルソン，
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2021522172A publication Critical patent/JP2021522172A/ja
Publication of JPWO2019209662A5 publication Critical patent/JPWO2019209662A5/ja
Publication of JP2021522172A5 publication Critical patent/JP2021522172A5/ja
Priority to JP2023213199A priority Critical patent/JP2024019603A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020557208A 2018-04-23 2019-04-19 軟骨ホーミングペプチドの複合体 Ceased JP2021522172A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023213199A JP2024019603A (ja) 2018-04-23 2023-12-18 軟骨ホーミングペプチドの複合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661577P 2018-04-23 2018-04-23
US62/661,577 2018-04-23
PCT/US2019/028406 WO2019209662A1 (en) 2018-04-23 2019-04-19 Conjugates of cartilage-homing peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023213199A Division JP2024019603A (ja) 2018-04-23 2023-12-18 軟骨ホーミングペプチドの複合体

Publications (3)

Publication Number Publication Date
JP2021522172A true JP2021522172A (ja) 2021-08-30
JPWO2019209662A5 JPWO2019209662A5 (https=) 2022-04-14
JP2021522172A5 JP2021522172A5 (https=) 2022-04-14

Family

ID=66429652

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557208A Ceased JP2021522172A (ja) 2018-04-23 2019-04-19 軟骨ホーミングペプチドの複合体
JP2023213199A Pending JP2024019603A (ja) 2018-04-23 2023-12-18 軟骨ホーミングペプチドの複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023213199A Pending JP2024019603A (ja) 2018-04-23 2023-12-18 軟骨ホーミングペプチドの複合体

Country Status (6)

Country Link
US (1) US20210252159A1 (https=)
EP (1) EP3784287A1 (https=)
JP (2) JP2021522172A (https=)
AU (1) AU2019261254A1 (https=)
CA (1) CA3097143A1 (https=)
WO (1) WO2019209662A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044894A2 (en) * 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
WO2017100700A2 (en) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides for renal therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2018210157B2 (en) * 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
CN107137716A (zh) * 2017-05-10 2017-09-08 北京林业大学 一种聚乙二醇偶联环形多肽iRGD和薯蓣皂苷元载药纳米粒子的制备
AU2018283161A1 (en) * 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044894A2 (en) * 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
WO2017100700A2 (en) * 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides for renal therapy

Also Published As

Publication number Publication date
JP2024019603A (ja) 2024-02-09
WO2019209662A1 (en) 2019-10-31
US20210252159A1 (en) 2021-08-19
AU2019261254A1 (en) 2020-10-15
CA3097143A1 (en) 2019-10-31
EP3784287A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
JP7378449B2 (ja) 軟骨ホーミングペプチド
JP7280193B2 (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
US11331393B2 (en) Renal-homing peptide conjugates and methods of use thereof
US11559580B1 (en) Tissue-homing peptide conjugates and methods of use thereof
JP2024015145A (ja) 欠失した軟骨ホーミングペプチド、及び、ペプチド複合体、及び、それらの使用方法
JP2024019603A (ja) 軟骨ホーミングペプチドの複合体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220406

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231225

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240524